Risk for nephrogenic systemic fibrosis with gadoteridol (ProHance) in patients who are on long-term hemodialysis
about
Toxicity of MRI and CT contrast agentsNephrogenic systemic fibrosis: a survey of nephrologists' perceptions and practices.Basic MR relaxation mechanisms and contrast agent designMRI CEST at 1T with large µeff Ln(3+) complexes T m(3+)-HPDO3A: An efficient MRI pH reporter.Primer on gadolinium chemistry.Type of MRI contrast, tissue gadolinium, and fibrosis.Nephrogenic systemic fibrosis: risk factors suggested from Japanese published cases.Pathophysiology of gadolinium-associated systemic fibrosisGd-based macromolecules and nanoparticles as magnetic resonance contrast agents for molecular imaging.Nephrogenic systemic fibrosis: review of 408 biopsy-confirmed casesUsing lanthanide ions in molecular bioimaging.Comments on the case report reported by Elmholdt et al.Diluted gadoteridol (ProHance®) causes mild ototoxicity in cochlear outer hair cells.3T MRI in the Evaluation of Brain Aneurysms Treated with Flow-Diverting Stents: Preliminary Experience.Gadolinium-Based Contrast Agents in Kidney Disease: A Comprehensive Review and Clinical Practice Guideline Issued by the Canadian Association of Radiologists.The Role of Equilibrium and Kinetic Properties in the Dissociation of Gd[DTPA-bis(methylamide)] (Omniscan) at near to Physiological Conditions
P2860
Q22306013-6539D8CA-9DAE-4538-9D83-C9D7DB6F7883Q24602293-AB4F114B-B087-479A-B5E0-C915691314E3Q27692546-84A0874C-9BA5-4BA7-82CC-FE05196A6A83Q30887522-63BD8793-DBE5-41FF-8F8F-13D7B8DFE97AQ33516622-73773F37-426F-477F-975E-C5C12F0E3302Q34602036-B69CC616-18BC-48D6-AE47-3CFE827FB37EQ36324674-6253CAC7-3B50-44F3-83E6-2840AAFD950BQ37139482-E9FEFD60-49EF-4506-9065-4A903F7BBFE9Q37142843-14489A7D-6723-4997-B3AB-B726EAFCEF90Q37875688-6A48F991-E386-4443-B6F2-D32CEBAE7CE4Q38318320-6119B472-63BC-49AF-9D9E-B96C03A38F66Q40339457-749CB860-2DA3-474C-83FF-FFCE1B981245Q45802575-4B8783CC-8CF2-4108-8F33-72DC9D2D4E55Q48383491-964FB18B-75C8-4E7D-A1F2-C52A9CC2C664Q55515077-EFD5CCA4-28E0-4663-9F50-A8DE4130B8AEQ57526983-C21F1FAF-D1A0-47BB-83CA-5A50B99901A9
P2860
Risk for nephrogenic systemic fibrosis with gadoteridol (ProHance) in patients who are on long-term hemodialysis
description
2008 nî lūn-bûn
@nan
2008 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Risk for nephrogenic systemic ...... are on long-term hemodialysis
@ast
Risk for nephrogenic systemic ...... are on long-term hemodialysis
@en
Risk for nephrogenic systemic ...... are on long-term hemodialysis
@nl
type
label
Risk for nephrogenic systemic ...... are on long-term hemodialysis
@ast
Risk for nephrogenic systemic ...... are on long-term hemodialysis
@en
Risk for nephrogenic systemic ...... are on long-term hemodialysis
@nl
prefLabel
Risk for nephrogenic systemic ...... are on long-term hemodialysis
@ast
Risk for nephrogenic systemic ...... are on long-term hemodialysis
@en
Risk for nephrogenic systemic ...... are on long-term hemodialysis
@nl
P2860
P356
P1476
Risk for nephrogenic systemic ...... are on long-term hemodialysis
@en
P2093
Robert F Reilly
P2860
P304
P356
10.2215/CJN.05721207
P407
P577
2008-05-01T00:00:00Z